D-1845-2019 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1845-2019 was initiated by Pfizer Inc. on Aug 14, 2019 and is designated Class II. Reason for recall: Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas. The recall status is terminated (terminated Jun 20, 2023). Affected quantity: a) 20,117 cartons; b) 2,502 cartons.

Recall details

Product Type
Drugs
Report Date
Sep 4, 2019
Initiation Date
Aug 14, 2019
Termination Date
Jun 20, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 20,117 cartons; b) 2,502 cartons

Product description

RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.

Reason for recall

Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.

Distribution pattern

Nationwide in the USA and Puerto Rico.

Code information

Lot #: a) AR5407, Exp 2022 FEB; b) CD4565, Exp 2022 FEB

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1845-2019
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-1845-2019. Report a data issue: hello@regdatalab.com.